163 related articles for article (PubMed ID: 22995624)
21. Discovery of a novel class of highly potent inhibitors of the p53-MDM2 interaction by structure-based design starting from a conformational argument.
Furet P; Masuya K; Kallen J; Stachyra-Valat T; Ruetz S; Guagnano V; Holzer P; Mah R; Stutz S; Vaupel A; Chène P; Jeay S; Schlapbach A
Bioorg Med Chem Lett; 2016 Oct; 26(19):4837-4841. PubMed ID: 27542305
[TBL] [Abstract][Full Text] [Related]
22. Mouse double minute antagonist Nutlin-3a enhances chemotherapy-induced apoptosis in cancer cells with mutant p53 by activating E2F1.
Ambrosini G; Sambol EB; Carvajal D; Vassilev LT; Singer S; Schwartz GK
Oncogene; 2007 May; 26(24):3473-81. PubMed ID: 17146434
[TBL] [Abstract][Full Text] [Related]
23. Identification of new inhibitors of Mdm2-p53 interaction via pharmacophore and structure-based virtual screening.
Atatreh N; Ghattas MA; Bardaweel SK; Rawashdeh SA; Sorkhy MA
Drug Des Devel Ther; 2018; 12():3741-3752. PubMed ID: 30464405
[TBL] [Abstract][Full Text] [Related]
24. Substituted 1,4-benzodiazepine-2,5-diones as alpha-helix mimetic antagonists of the HDM2-p53 protein-protein interaction.
Cummings MD; Schubert C; Parks DJ; Calvo RR; LaFrance LV; Lattanze J; Milkiewicz KL; Lu T
Chem Biol Drug Des; 2006 Mar; 67(3):201-5. PubMed ID: 16611213
[TBL] [Abstract][Full Text] [Related]
25. Design, synthesis and biological evaluation of novel potent MDM2/p53 small-molecule inhibitors.
Ivanenkov YA; Vasilevski SV; Beloglazkina EK; Kukushkin ME; Machulkin AE; Veselov MS; Chufarova NV; Chernyaginab ES; Vanzcool AS; Zyk NV; Skvortsov DA; Khutornenko AA; Rusanov AL; Tonevitsky AG; Dontsova OA; Majouga AG
Bioorg Med Chem Lett; 2015 Jan; 25(2):404-9. PubMed ID: 25479770
[TBL] [Abstract][Full Text] [Related]
26. Design, synthesis and in vitro and in vivo antitumour activity of 3-benzylideneindolin-2-one derivatives, a novel class of small-molecule inhibitors of the MDM2-p53 interaction.
Zheng GH; Shen JJ; Zhan YC; Yi H; Xue ST; Wang Z; Ji XY; Li ZR
Eur J Med Chem; 2014 Jun; 81():277-88. PubMed ID: 24852275
[TBL] [Abstract][Full Text] [Related]
27. MDM2 non-genotoxic inhibitors as innovative therapeutic approaches for the treatment of pediatric malignancies.
Tisato V; Norcio A; Voltan R; Celeghini C; Zella D; Secchiero P
Curr Med Chem; 2013; 20(17):2226-36. PubMed ID: 23458617
[TBL] [Abstract][Full Text] [Related]
28. Inhibitors of MDM2 and MDMX: a structural perspective.
Riedinger C; McDonnell JM
Future Med Chem; 2009 Sep; 1(6):1075-94. PubMed ID: 21425995
[TBL] [Abstract][Full Text] [Related]
29. Efficient reactivation of p53 in cancer cells by a dual MdmX/Mdm2 inhibitor.
Qin L; Yang F; Zhou C; Chen Y; Zhang H; Su Z
J Am Chem Soc; 2014 Dec; 136(52):18023-33. PubMed ID: 25453499
[TBL] [Abstract][Full Text] [Related]
30. Simulation of MDM2 N-terminal domain conformational lability in the presence of imidazoline based inhibitors of MDM2-p53 protein-protein interaction.
Gureev M; Novikova D; Grigoreva T; Vorona S; Garabadzhiu A; Tribulovich V
J Comput Aided Mol Des; 2020 Jan; 34(1):55-70. PubMed ID: 31781989
[TBL] [Abstract][Full Text] [Related]
31. Novel inhibitors of the MDM2-p53 interaction featuring hydrogen bond acceptors as carboxylic acid isosteres.
Gonzalez AZ; Li Z; Beck HP; Canon J; Chen A; Chow D; Duquette J; Eksterowicz J; Fox BM; Fu J; Huang X; Houze J; Jin L; Li Y; Ling Y; Lo MC; Long AM; McGee LR; McIntosh J; Oliner JD; Osgood T; Rew Y; Saiki AY; Shaffer P; Wortman S; Yakowec P; Yan X; Ye Q; Yu D; Zhao X; Zhou J; Olson SH; Sun D; Medina JC
J Med Chem; 2014 Apr; 57(7):2963-88. PubMed ID: 24601644
[TBL] [Abstract][Full Text] [Related]
32. Efficient p53 activation and apoptosis by simultaneous disruption of binding to MDM2 and MDMX.
Hu B; Gilkes DM; Chen J
Cancer Res; 2007 Sep; 67(18):8810-7. PubMed ID: 17875722
[TBL] [Abstract][Full Text] [Related]
33. Design and synthesis of new bioisosteres of spirooxindoles (MI-63/219) as anti-breast cancer agents.
Kumar A; Gupta G; Bishnoi AK; Saxena R; Saini KS; Konwar R; Kumar S; Dwivedi A
Bioorg Med Chem; 2015 Feb; 23(4):839-48. PubMed ID: 25618595
[TBL] [Abstract][Full Text] [Related]
34. Affinity-based screening of MDM2/MDMX-p53 interaction inhibitors by chemical array: identification of novel peptidic inhibitors.
Noguchi T; Oishi S; Honda K; Kondoh Y; Saito T; Kubo T; Kaneda M; Ohno H; Osada H; Fujii N
Bioorg Med Chem Lett; 2013 Jul; 23(13):3802-5. PubMed ID: 23726030
[TBL] [Abstract][Full Text] [Related]
35. Proteomimetic libraries: design, synthesis, and evaluation of p53-MDM2 interaction inhibitors.
Lu F; Chi SW; Kim DH; Han KH; Kuntz ID; Guy RK
J Comb Chem; 2006; 8(3):315-25. PubMed ID: 16677000
[TBL] [Abstract][Full Text] [Related]
36. Discovery of potent and selective spiroindolinone MDM2 inhibitor, RO8994, for cancer therapy.
Zhang Z; Ding Q; Liu JJ; Zhang J; Jiang N; Chu XJ; Bartkovitz D; Luk KC; Janson C; Tovar C; Filipovic ZM; Higgins B; Glenn K; Packman K; Vassilev LT; Graves B
Bioorg Med Chem; 2014 Aug; 22(15):4001-9. PubMed ID: 24997575
[TBL] [Abstract][Full Text] [Related]
37. Rapid screening of protein-protein interaction inhibitors using the protease exclusion assay.
Nirantar SR; Li X; Siau JW; Ghadessy FJ
Biosens Bioelectron; 2014 Jun; 56():250-7. PubMed ID: 24508816
[TBL] [Abstract][Full Text] [Related]
38. Induction of p53-dependent senescence by the MDM2 antagonist nutlin-3a in mouse cells of fibroblast origin.
Efeyan A; Ortega-Molina A; Velasco-Miguel S; Herranz D; Vassilev LT; Serrano M
Cancer Res; 2007 Aug; 67(15):7350-7. PubMed ID: 17671205
[TBL] [Abstract][Full Text] [Related]
39. Potential for treatment of liposarcomas with the MDM2 antagonist Nutlin-3A.
Müller CR; Paulsen EB; Noordhuis P; Pedeutour F; Saeter G; Myklebost O
Int J Cancer; 2007 Jul; 121(1):199-205. PubMed ID: 17354236
[TBL] [Abstract][Full Text] [Related]
40. Inhibiting mechanism of small molecule toward the p53-MDM2 interaction: A molecular dynamic exploration.
Chen J; Wang J; Pang L; Zhu W
Chem Biol Drug Des; 2018 Oct; 92(4):1763-1777. PubMed ID: 29877036
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
